News

The relative risk reduction was 94% in patients 65 years of age or older in clinical trials.

The American Society of Hematology debuted its Health Equity Rounds series, which are interactive, case-based discussions with an interdisciplinary panel to include hematologists, health equity/public health experts, patients, and patient advocates.

Engagement had positive associations with higher comfort with technology, visual acuity, nAMD diagnosis, and the number of intravitreal injections.

Patients with COVID-19 were not at an increased risk of developing CDI.

A look into how Allegheny Health Network launched its multi-specialty referral system for post-hospitalized COVID-19 patients.

Dr. Moody speaks to how these E/M code changes affect billing documentation and patient care.

Children with persistent sleep problems had greater impairments across the different outcomes other than cognitive skills.

Dr. Jellinger discusses the lipid section of the DCRM guidelines, the role of combination therapies in lowering LDL and what is coming next for the field of diabetes in 2022.

Results from the RELIEVE-AD study were consistent with patient-reported outcomes in clinical trials.

Apremilast is now the first and only treatment approved in adult patients with plaque psoriasis across all severities.

NYU Langone is developing a comprehensive care program that includes psychiatric evaluations during postpartum OBGYN care.

Investigators suggested a more efficient sleep diagnosis algorithm be created to detail the connection between ADHD and sleep in children.

Data show the proportion of infants with influenza aged <6 months ranged from 1.0 – 2.6% among all infant hospitalizations in the 2019 influenza season.

The TPV system expands transcatheter therapy options for patients with congenital heart valve disease.

Both PEARL 1 and PEARL 2 enrolled over 2000 adults and adolescents patients selected from 48 countries.

The treatment is approved as either a monotherapy or an adjunctive therapy with either lithium or valproate.

Dr. Rosmarin details the TruE-V clinical trial, and speaks to what could eventually be the first FDA approved medicine for vitiligo.

Weight loss could be beneficial for NASH and NAFLD patients.

Fuad El Rassi talks about the Grady Comprehensive Sickle Cell center, the COVID-19 vaccine, and the data he presented at ASH.

The treatment represents the first approved treatment that directly targets sickle hemoglobin polymerization.

In a Dutch population, the prevalence of MMD increased with older age, lower spherical equivalent of refractive error, and higher axial length.

Cardiologists have utilized new technologies during the COVID-19 pandemic.

TARGET-NASH as now expanded into European centers.

With the concept of a “twindemic” becoming more realistic than ever, experts are stressing that preventive practices, and vaccination, address both flu and COVID-19.

Data on humidity levels in 48 states for over 12 years were featured in the study.

Findings from the SWAY trial highlight a pressing need for varying and more personalized treatment methods for patients.

Topical pimecrolimus 1% treatment had unsatisfactory results, while combination microneedling and topical pimecrolimus treatment showed a favorable outcome.